As of 2025-07-18, the Fair Value of Hyloris Pharmaceuticals SA (HYL.BR) is -1.13 EUR. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 6.88 EUR, the upside of Hyloris Pharmaceuticals SA is -116.46%.
With the market price of 6.88 EUR and our fair value calculation, Hyloris Pharmaceuticals SA (HYL.BR) is not a good investment. Investing in HYL.BR stocks now will result in a potential loss of 116.46%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 5Y Avg | |
| Net income | -7.15 | -11.58 | -11.91 | -15.38 | -6.34 | -10.47 |
| YoY growth | -23.89% | -62.03% | -2.82% | -29.19% | 58.76% | -11.83% |
| Market Cap (mil) | 192.64 |
| P/E | |
| Forward P/E |
| EPS | -0.23 |
| Avg earnings growth rate | -11.83% |
| TTM earnings | -6.34 |